Preprint · 2026 · Open access
Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis
Research Square · Published 21 September 2026 · DOI 10.21203/rs.3.rs-10983952/v1
In brief
“Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis” is a 2026 preprint by Mansi Joshi and 6 co-authors, published in Research Square. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Research Square.
- Citations
- 0
- References
- 43
- Authors
- 7
Abstract
Background Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer (BC), for which targeted medicine options are still very limited. This study provides comprehensive experimental evidences on neratinib as a molecularly targetable inhibitor for treatment, at least for basal-like and mesenchymal-like TNBC subtypes, where both EGFR and STAT3 activation are pronounced. Methods Molecular docking was used for in silico evaluation of neratinib binding to STAT3 and EGFR. TCGA and METABRIC data were used for gene expression and pathway enrichment analysis. The phospho-STAT3 BRET assay was used to measure STAT3 dimerization and activation. Phospho-proteome array and immunoblotting were used for validation of Neratinib effect on the EGFR/ERK/STAT3 signaling axis. The effect of neratinib on tumor growth, metastasis, and angiogenesis was assessed in TNBC orthotopic xenografts using in vivo bioluminescence imaging, immunohistochemistry, and Western blot. Results By using in silico molecular docking, for the first time neratinib was found to directly bind on the STAT3 SH2 domain, in addition to its known binding on EGFR kinase domain. TCGA and METABRIC cohort analyses confirmed EGFR overexpression in TNBC linked with poor patient survival (P ≤ 0.0001) and upregulation of EGFR and the MAPK signaling cascade. Association between EGFR overexpression and increased non-canonical STAT3 activation was established in TNBC cell types. Neratinib showed substantial inhibition of EGF/ERK/STAT3 signaling axis in phospho-proteome arrays, thereby establishing its control mechanism over STAT3 activation. STAT3 inhibition showed reduced dimerization and nuclear translocation, thereby suppressing transcription of its downstream target genes. Consequently, neratinib treatment showed reduced survival and proliferation, induced apoptosis, and reduced migration/invasiveness of the TNBC cells tested. Further, in a preclinical orthotopic TNBC tumor xenograft model, neratinib treatment has shown significantly retarded tumor growth, organ metastasis, and angiogenesis. Conclusion Thus, this study provides staggered evidences showing that neratinib, the small molecule drug, can serve as a dual-target inhibitor for treatment of cancer with elevated activation of both EGFR and STAT3. The new evidences indicate that repurposing neratinib may extend significant benefit for treatment of certain subtypes of TNBCs.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Joshi, M., Dimri, S., Ghosh, S., Dey, P., Gadewal, N., Das, G., & De, A. (2026). Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis. Research Square. https://doi.org/10.21203/rs.3.rs-10983952/v1
MLA 9
Joshi, Mansi, et al. “Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis.” Research Square, 2026. https://doi.org/10.21203/rs.3.rs-10983952/v1.
Chicago
Joshi, Mansi, Shalini Dimri, Shaonlee Ghosh, Pranay Dey, Nikhil Gadewal, Gourab Das, and Abhijit De. 2026. “Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis.” Research Square. https://doi.org/10.21203/rs.3.rs-10983952/v1.
Harvard
Joshi, M. et al. (2026) ‘Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis’, Research Square. doi:10.21203/rs.3.rs-10983952/v1.
IEEE
M. Joshi et al., “Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis,” Research Square, 2026, doi: 10.21203/rs.3.rs-10983952/v1.
BibTeX
@misc{joshi2026expanding,
title = {{Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis}},
author = {Joshi, Mansi and Dimri, Shalini and Ghosh, Shaonlee and Dey, Pranay and Gadewal, Nikhil and Das, Gourab and De, Abhijit},
howpublished = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-10983952/v1},
url = {https://doi.org/10.21203/rs.3.rs-10983952/v1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- neratinib
- triple-negative breast cancer
- EGFR
- STAT3
- ERK signaling
- HER2-targeted therapy
- drug repurposing
- MAPK signaling
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Joshi, M., Dimri, S., Ghosh, S., Dey, P., Gadewal, N., Das, G., & De, A. (2026). Expanding the Scope of HER2-targeted Medicine Neratinib to Combat Triple- Negative Breast Cancer by Inhibiting the EGFR-ERK-STAT3 Signaling Axis. Research Square. https://doi.org/10.21203/rs.3.rs-10983952/v1
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Research Square: sign in and open the full text from this page.
Who wrote this paper?
Mansi Joshi, Shalini Dimri, Shaonlee Ghosh, Pranay Dey, Nikhil Gadewal, Gourab Das, Abhijit De.
What is the DOI of this paper?
10.21203/rs.3.rs-10983952/v1, permanently at https://doi.org/10.21203/rs.3.rs-10983952/v1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.